Cargando…

The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study

Background: The incidence and risk of urinary tract infection (UTI) in patients with type 2 diabetes mellitus (T2DM) who use sodium glucose co-transporter-2 (SGLT2) inhibitors are still controversial. Therefore, this study aimed to investigate the incidence and risk factors of using SGLT2 inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uitrakul, Suriyon, Aksonnam, Krittika, Srivichai, Pimchanok, Wicheannarat, Sorawit, Incomenoy, Supatcha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785475/ https://www.ncbi.nlm.nih.gov/pubmed/36547992 http://dx.doi.org/10.3390/medicines9120059

Ejemplares similares

Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study
por: Chanawong, Apichaya, et al.
Publicado: (2023)

Comparative Safety and Effectiveness of Heterologous CoronaVac–ChAdOx1 versus Homologous CoronaVac Vaccination in a Real-World Setting: A Retrospective Cohort Study
por: Ruenkham, Ayakarn, et al.
Publicado: (2023)

A Pilot Study of Antibiotic Regimens for Infections Caused by Acinetobacter baumannii in a Secondary Hospital in Thailand
por: Suphansatit, Ronnawich, et al.
Publicado: (2020)

Clinical outcomes and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant Acinetobacter baumannii in cancer patients
por: Katip, Wasan, et al.
Publicado: (2017)

A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients: A Propensity Score-Matched Analysis
por: Katip, Wasan, et al.
Publicado: (2020)

Short-Course Versus Long-Course Colistin for Treatment of Carbapenem-Resistant A. baumannii in Cancer Patient
por: Katip, Wasan, et al.
Publicado: (2021)

Clinical Efficacy and Nephrotoxicity of the Loading Dose Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients
por: Katip, Wasan, et al.
Publicado: (2021)

Vitamin D Levels in Patients with Active and Remission Graves’ Disease
por: Rattanamusik, Natapon, et al.
Publicado: (2023)

Recurrent urinary tract infection associated with SGLT‐2 inhibitor in type 2 diabetes mellitus patient: A case report
por: Hazique, Mohammad, et al.
Publicado: (2023)

Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes
por: Tanrıverdi, Mustafa, et al.
Publicado: (2023)

Efficacy of loading dose colistin versus carbapenems for treatment of extended spectrum beta lactamase producing Enterobacteriaceae
por: Katip, Wasan, et al.
Publicado: (2021)

The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
por: Pitt, Bertram, et al.
Publicado: (2021)

Influence of Concentration and Temperature on Stability of Imipenem Focused on Solutions for Extended Infusion
por: Sornsuvit, Chuleegone, et al.
Publicado: (2021)

Knowledge and attitude toward emergency contraceptive pills among first-year undergraduate students in Southern Thailand
por: Yongpraderm, Siranee, et al.
Publicado: (2022)

Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea
por: Yang, Hyeri, et al.
Publicado: (2022)

Levofloxacin Use in Patients with Suspected Tuberculosis in a Community Hospital, Thailand: A Pilot Study
por: Khongyot, Thanawat, et al.
Publicado: (2022)

Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis
por: Chung, Mu-Chi, et al.
Publicado: (2022)

SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
por: Tamez-Perez, Héctor Eloy, et al.
Publicado: (2017)

LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2
por: Powell, David R, et al.
Publicado: (2015)

The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

Effective formative assessment for pharmacy students in Thailand: lesson learns from a school of pharmacy in Thailand
por: Sottiyotin, Tida, et al.
Publicado: (2023)

SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits
por: Leoncini, Giovanna, et al.
Publicado: (2021)

A real-world study on SGLT2 inhibitors and diabetic kidney disease progression
por: Liu, Allen Yan Lun, et al.
Publicado: (2022)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D)
por: Ryan, Patrick B., et al.
Publicado: (2018)

Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
por: El Hage, Lea, et al.
Publicado: (2020)

Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?
por: Nomiyama, Takashi
Publicado: (2020)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
por: Suzuki, Yuta, et al.
Publicado: (2022)

Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
por: Jeong, Su Jin, et al.
Publicado: (2021)

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
por: McGovern, Andrew, et al.
Publicado: (2017)

Prevalence and Associated Factors of Anemia among Breast Cancer Patients Undergoing Chemotherapy: A Prospective Study
por: Muthanna, Fares M. S, et al.
Publicado: (2022)

Prevalence of Bacterial Urinary Tract Infection Among Patients With Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter-2 Inhibitors: A Prospective Real-World Setting Study
por: Ferwani, Pankaj, et al.
Publicado: (2022)

Real-world evidence: Telemedicine for complicated cases of urinary tract infection
por: Daumeyer, Natalie M., et al.
Publicado: (2023)

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
por: Jung, Chang Hee, et al.
Publicado: (2014)

Time Trends in Spain from 2001 to 2018 in the Incidence and Outcomes of Hospitalization for Urinary Tract Infections in Patients with Type 2 Diabetes Mellitus
por: López-de-Andrés, Ana, et al.
Publicado: (2020)

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
por: McGovern, Andrew, et al.
Publicado: (2017)

SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world
por: Marx, Nikolaus, et al.
Publicado: (2023)

SGLT2 and cancer
por: Wright, Ernest M.
Publicado: (2020)

INCIDENCE OF URINARY TRACT INFECTION AFTER CYSTOGRAPHY
por: Martins, Joana Sousa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hja8cr67gantlmvthedblk1gg6